AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
- Details
Shire announced that lifitegrast met its primary and secondary endpoints
- Details
Investigators found that the latest concept in the prevention of post-cataract posterior capsule opacification appears promising.
Read more: Protective membrane shows promise in reducing PCO
- Details
Adherence patterns established during the first year of treatment typically don’t change over time.
Read more: Glaucoma medication adherence: Early habits stick
- Details
University of Leeds researcher is developing an IOL for presbyopia made from liquid crystal.
- Details
Citron Research accuses Canadian-based pharmaceutical company Valeant of massive fraud.
- Details
FDA has requested an additional information for Shire’s dry eye disease drug, lifitegrast.